Prescription Required
In stock
Manufacturer
ACTAVIS PHARMA/
SKU
00472037045

betamethasone va 0.1% cream

Generic
$54.29 / tube
$57.11 / tube
$2.82 / tube
+ -
1,000 tubes Available
Total Price:

Uses

Betamethasone shares the actions of the other topical corticosteroids and is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

For systemic uses of betamethasone,

Dosage and Administration

Betamethasone dipropionate and valerate are applied topically. Betamethasone dipropionate preparations and betamethasone valerate preparations should not be used with occlusive dressings and patients should be warned that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive, unless directed by a clinician.

Concentrations of the dipropionate and valerate preparations usually are expressed in terms of betamethasone. Concentration of betamethasone valerate foam is expressed in terms of betamethasone valerate.

Topical preparations of betamethasone dipropionate usually are applied sparingly in thin films and are rubbed gently into the affected area once or twice daily. Because betamethasone dipropionate preparations formulated in an optimized (augmented) vehicle are among the most potent topical corticosteroid preparations currently available, the manufacturers state that dosage of betamethasone dipropionate 0.05% ointments, creams, gels, or lotions in optimized (augmented) vehicles should not exceed 45 g, 45 g, 50 g, or 50 mL per week, respectively. Some manufacturers also state that duration of therapy with these optimized preparations should not exceed 2 weeks.

Topical betamethasone 0.1% creams and ointments (as valerate) usually are applied sparingly in thin films and are rubbed gently into the affected area 1-3 times daily. However, once- or twice-daily administration of these preparations often is effective. Topical betamethasone valerate 0.1% solutions are applied sparingly (e.g., a few drops) and are rubbed gently into the affected area twice daily, in the morning and evening. Dosage of the topical solution may be increased in patients with resistant dermatoses. However, dosing frequency should be decreased to once daily following clinical improvement.

For relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp, betamethasone valerate 0.12% foam should be applied twice daily, in the morning and evening. For application to the scalp, the can containing betamethasone valerate foam should be inverted and small amounts of the preparation placed on a saucer or other cool surface. The foam should not be dispensed directly to the hands since the foam will begin to melt immediately upon contact with warm skin. Small amounts of the preparation should be massaged gently into the scalp until the foam disappears and entire scalp area has been treated.

For the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, or tinea corporis caused by Trichophyton mentagrophytes, T. rubrum, or Epidermophyton floccosum, the fixed-combination cream or lotion containing betamethasone 0.05% and clotrimazole 1% should be applied sparingly and rubbed gently into the affected area twice daily, in the morning and evening. If clinical improvement does not occur after 1 week in the treatment of tinea cruris or tinea corporis or after 2 weeks in the treatment of tinea pedis, the diagnosis should be reevaluated. The manufacturer states that dosage of the combination cream or lotion should not exceed 45 g or 45 mL per week, respectively, and duration of therapy with these combination preparations should not exceed 2 weeks in the treatment of tinea cruris or tinea corporis or 4 weeks in the treatment of tinea pedis. Occlusive dressings should not be used with these combination preparations.

For the topical treatment of plaque psoriasis (psoriasis vulgaris) in adults 18 years of age or older, the fixed-combination ointment containing betamethasone 0.05% and calcipotriene 0.005% should be applied and rubbed gently into the affected area until absorbed once daily. The combination ointment should not be applied to greater than 30% of body surface area. The manufacturer states that dosage of the combination ointment should not exceed 100 g per week, and duration of therapy should not exceed 4 consecutive weeks. Occlusive dressings should not be used with the combination preparation, unless directed by a clinician. The fixed-combination ointment should not be applied to the face, axillae, or groin area. The fixed-combination ointment should not be used in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with preexisting atrophy at the treatment site. Contact with the eyes should be avoided. If irritation occurs, therapy with the fixed-combination ointment should be discontinued and appropriate treatment instituted. Patients should wash their hands after applying the drug. The fixed-combination ointment is not for ophthalmic, oral, or intravaginal use.

For the topical treatment of moderate to severe plaque psoriasis (psoriasis vulgaris) of the scalp in adults 18 years of age or older, the fixed-combination suspension containing betamethasone 0.05% and calcipotriene 0.005% should be applied to the affected area(s) on the scalp once daily for 2 weeks or until cleared. The manufacturer states that dosage of the combination suspension should not exceed 100 g per week, and duration of therapy should not exceed 8 weeks. Occlusive dressings should not be used with the combination preparation, unless directed by a clinician. The combination suspension should not be applied to the face, axillae, or groin area. In addition, the suspension should not be used in patients with erythrodermic, exfoliative, or pustular psoriasis or in patients with preexisting atrophy at the treatment site. Contact with the eyes should be avoided; eye irritation may occur. The bottle containing the suspension should be shaken prior to each use; patients should wash their hands after applying the drug. The fixed-combination suspension is not for ophthalmic, oral, or intravaginal use.

Because calcipotriene may increase the effect of ultraviolet radiation to induce skin tumors, patients who apply the fixed-combination ointment or suspension to exposed areas of the body should avoid exposure to natural or artificial (e.g., sunlamps, tanning booths) sunlight and limit or avoid phototherapy.

Cautions

Betamethasone shares the toxic potentials of other topical corticosteroids, and the usual precautions of corticosteroid therapy should be observed. If fixed combinations of betamethasone with calcipotrinene or with clotrimazole are used, the precautions and contraindications associated with calcipotrinene or clotrimazole must be considered. and

Betamethasone dipropionate gels, lotions, creams, and ointments, particularly those in optimized (augmented) vehicles, are some of the most potent topical corticosteroid preparations currently available. Because of their potency, these preparations can suppress the hypothalamic-pituitary-adrenal (HPA) axis following topical application, and reversible HPA-axis suppression has occurred following topical dosages as low as 7 g, 7 mL, or 7 g of the 0.05% betamethasone dipropionate gel, lotion, or cream, respectively, in optimized (augmented) vehicles (3.5 mg of betamethasone) daily. Reversible HPA-axis suppression also has occurred following repeated topical dosages of 14 g of the 0.05% ointment in an optimized (augmented) vehicle (7 mg of betamethasone) daily in patients with psoriasis, and minimal suppression has occurred following 3.5 g of this ointment (1.75 mg of betamethasone) twice daily for 2-3 weeks in healthy individuals and in patients with psoriasis or eczema.

Pediatric Precautions

Lotrisone preparations are not recommended for use in the treatment of diaper dermatitis or for use in children younger than 17 years of age. Use of Diprosone or Diprolene preparations in children 12 years of age or younger is not recommended. In addition, the safety and efficacy of Luxiq foam, Taclonex ointment, and Taclonex Scalp topical suspension in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk of systemic adverse effects than are adults when treated with topical agents; pediatric patients younger than 12 years of age may be at particular risk of systemic adverse effects when treated with topical corticosteroids.

In open-label studies in pediatric patients receiving topical betamethasone dipropionate preparations for 2-3 weeks for treatment of atopic dermatitis, HPA-axis or adrenal suppression occurred in 73% of children 6-12 years of age who received the 0.05% lotion, 32% of children 3 months to 12 years of age who received the 0.05% cream in an optimized [augmented] vehicle, 28% of children 6 months to 12 years of age who received the 0.05% ointment, and 23% of children 2-12 years of age who received the 0.05% cream. The proportion of patients with adrenal suppression in these studies increased with decreasing age. If betamethasone dipropionate or betamethasone valerate is used for topical treatment of corticosteroid-responsive dermatoses in children, the usual precautions associated with topical corticosteroid therapy in pediatric patients should be observed.

Write Your Own Review
You're reviewing:BETAMETHASONE VA 0.1% CREAM
Your Rating